Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    AL001

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alzamend AL001 Shows Bioequivalence, Better Brain Delivery
    Alzamend AL001 Shows Bioequivalence, Better Brain Delivery

    26 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/alzamend-neuro-reports-positive-topline-data-from-phase-ii-clinical-trial-of-al001-lithium-in-brain-study-al001-achieves-bioequivalence-and-demonstrates-superior-brain-delivery-across-all-measured-brain-regions-302725991.html

    PR NEWSWIRE
    26 Mar 2026
    Share Share
    Alzamend starts Phase II trial of AL001 at Massachusetts Hospital
    Alzamend starts Phase II trial of AL001 at Massachusetts Hospital

    18 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2025/03/18/3044409/0/en/Alzamend-Neuro-Announces-Initiation-Date-of-Phase-II-Clinical-Trial-of-AL001-for-Treatment-of-Major-Depressive-Disorder-to-take-Place-at-Massachusetts-General-Hospital.html

    GLOBENEWSWIRE
    18 Mar 2025
    Share Share
    Alzamend Neuro Announces Initiation of PI First-in-Human Clinical Trial of AL001
    Alzamend Neuro Announces Initiation of PI First-in-Human Clinical Trial of AL001

    13 Sep 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210913005330/en

    BUSINESSWIRE
    13 Sep 2021
    Share Share
    Alzamend Neuro and Altasciences to conduct a Phase I study for AL001.
    Alzamend Neuro and Altasciences to conduct a Phase I study for AL001.

    17 Aug 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210817005396/en

    BUSINESSWIRE
    17 Aug 2021
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.